Enhanced Blood Coagulation and Fibrinolysis in a Patient with Primary Amyloidosis

E Perlin; P Brakman; H. S Berg; P. T Kirchner; R. B Moquin; T Astrup

doi:10.1055/s-0038-1653650

Thrombosis and Haemostasis, Inhaltsverzeichnis

Thromb Haemost 1971; 26(01): 009-014
DOI: 10.1055/s-0038-1653650

Originalarbeiten – Original Articles – Travaux Originaux

Schattauer GmbH

Enhanced Blood Coagulation and Fibrinolysis in a Patient with Primary Amyloidosis

Autoren

E Perlin

¹Hematology Branch, Naval Hospital, National Naval Medical Center, Bethesda, Maryland 20014

²Institute for Medical Research of the James F. Mitchell Foundation, Washington, D. C. 20015
P Brakman

¹Hematology Branch, Naval Hospital, National Naval Medical Center, Bethesda, Maryland 20014

²Institute for Medical Research of the James F. Mitchell Foundation, Washington, D. C. 20015
H. S Berg

¹Hematology Branch, Naval Hospital, National Naval Medical Center, Bethesda, Maryland 20014

²Institute for Medical Research of the James F. Mitchell Foundation, Washington, D. C. 20015
P. T Kirchner

¹Hematology Branch, Naval Hospital, National Naval Medical Center, Bethesda, Maryland 20014

²Institute for Medical Research of the James F. Mitchell Foundation, Washington, D. C. 20015
R. B Moquin

¹Hematology Branch, Naval Hospital, National Naval Medical Center, Bethesda, Maryland 20014

²Institute for Medical Research of the James F. Mitchell Foundation, Washington, D. C. 20015
T Astrup

¹Hematology Branch, Naval Hospital, National Naval Medical Center, Bethesda, Maryland 20014

²Institute for Medical Research of the James F. Mitchell Foundation, Washington, D. C. 20015

Abstract

Summary

A case of primary amyloidosis associated with blood coagulation abnormalities is presented. Enhancement of coagulation, suspected because of acceleration of the thromboplastin activation test and of abnormal thrombelastography patterns, was confirmed by the presence of thrombi observed at necropsy. Increased systemic fibrinolysis was evidenced by accelerated clot lysis, increased euglobulin activity, and decreased plasminogen. The presence of fragmented red cells in the peripheral blood smear was consistent with a microangiopathic process. Despite these abnormalities, there were no major changes in levels of coagulation factors. Episodes of massive bleeding occurred when major changes in coagulation or fibrinolysis were absent, supporting the suggestion that vascular infiltration by amyloid is a major cause of hemorrhage.

Volltext

Referenzen

References
1 Astrup T, Albrechtsen OK. Serum effects following tissue thromboplastin infusion. Thrombos. Diathes. haemorrh. (Stuttg) 21: 117 1969;
2 Astrup T, Brahman P, Nissen U. The estimation of fibrinogen. A revision. Scand. J. clin. Lab. Invest 17: 57 1965;
3 Astrup T, Ollendorff P. Estimation of thromboplastin activation in plasma. Scand. J. clin. Lab. Invest 13: 377 1961;
4 Bowie EJ, Maldonado JE, Brown AL, Didisheim P, Owen GA. Intravascular coagulation in systemic amyloidosis. Thrombos. Diathes. haemorrh. (Stuttg) XXVI (Suppl.) 305 1969;
5 Brakman P. Fibrinolysis: A Standardized Fibrin Plate Method and a Fibrinolytic Assay of Plasminogen. Scheltema and Holkema NY; Amsterdam: 1967
6 Brakman P.O.K, Albrechtsen T. Astrup A comparative study of coagulation and fibrinolysis in blood from normal men and women. Brit. J. Haemat 12: 74 1966;
7 Brakman P, Mohler ER, Astrup T. A group of patients with impaired plasma fibrinolytic system and selective inhibition of tissue activator induced fibrinolysis. Scand. J. Haemat 03: 389 1966;
8 Brecher J, Gronkite EP. Morphology and enumeration of blood platelets. J. appl. Physiol 03: 375 1950;
9 Bull BS, Rubenberg ML, Dade JV, Brain MG. Microangiopathic hemolytic anemia: Mechanisms of red cell fragmentation. In vitro studies. Brit. J. Haemat 14: 643 1968;
10 Ghakrabarti R, Fearnley GR, Hocking ED. Effect of corticosteroid therapy on fibrinolysis in patients with inflammatory and non-inflammatory conditions. Brit. med. J 01: 534 1964;
11 Hartert A. Die Thromboelastographie. Eine Methode zur physikalischen Analyse des Blutgerinnungsvorganges. Z. exp. Med 117: 189 1951;
12 Kowalski E, Kopec M, Niewiarowski S. Evaluation of the euglobulin method for determination of fibrinolysis. J. clin. Path 12: 215 1959;
13 Lasch H-G, Keene DL, Huth K, Sandritter W. Pathophysiology, clinical manifestations and therapy in consumption-coagulopathy. Amer. J. Cardiol 20: 381 1967;
14 Parfentjev IA, Johnson ML, Gliffton EE. The determination of plasma fibrinogen by turbidity with ammonium sulfate. Arch. Biochem 46: 470 1953;
15 Proctor RR, Rapaport SE. Partial thromboplastin time with kaolin. Amer. J. clin. Path 36: 212 1961;
16 Pudlak P, Vorlova Z, Stejskal J. Unusual hemorrhagic diathesis and a typical primary amyloidosis. Acta haemat. (Basel) 25: 321 1961;
17 Quick AJ. Hemorrhagic Diseases. 391 Lea and Febiger; Philadelphia: 1966
18 Redleaf PD, Davis RB, Kucinski G, Hoilund L, Gans H. Amyloidosis with an unusual bleeding diathesis. Ann. intern. Med 58: 347 1963;
19 Rodriguez-Erdmann F. Bleeding due to increased intravascular blood coagulation. New Engl. J. Med 273: 1370 1965;
20 Verstraete M, Vermylen G, Vermylen J, Vandenbroucke J. Excessive consumption of blood coagulation components as cause of hemorrhagic diathesis. Amer. J. Med 38: 899 1965;